Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
about
A comparison of different antibiotic regimens for the treatment of infective endocarditisAntibiotic therapy for treatment of infective endocarditisEfficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trialsGentamicin-induced ototoxicity and nephrotoxicity vary with circadian time of treatment and entail separate mechanisms.Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Clinical management of Staphylococcus aureus bacteremia: a review.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the EuClinical experience with daptomycin in Europe: the first 2.5 years.Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomesMethicillin-resistant Staphylococcus aureus USA300 clone as a cause of Lemierre's syndrome.Multivalvular infective endocarditis in pregnancy presenting with septic pulmonary emboli.Predictors of mortality in Staphylococcus aureus BacteremiaA comparative study for the inactivation of multidrug resistance bacteria using dielectric barrier discharge and nano-second pulsed plasma.Combination therapy for treatment of infections with gram-negative bacteria.Combination therapy with an aminoglycoside for Staphylococcus aureus endocarditis and/or persistent bacteremia is associated with a decreased rate of recurrent bacteremia: a cohort study.Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus BacteremiaInvasive community-associated MRSA infections: epidemiology and antimicrobial management.The strategy of antibiotic use in critically ill neutropenic patientsThe efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms.Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy.Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA).Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.Aminoglycoside therapy in infectious diseases.Enterococcus faecalis infective endocarditis: focus on clinical aspects.New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections.Vancomycin-associated renal dysfunction: where are we now?The Nephrotoxicity of VancomycinRaf-kinase inhibitor GW5074 shows antibacterial activity against methicillin-resistant Staphylococcus aureus and potentiates the activity of gentamicin.Use of bacterial whole-genome sequencing to understand and improve the management of invasive Staphylococcus aureus infections.Significant Publications on Infectious Diseases Pharmacotherapy in 2016.No increased risk of acute kidney injury after a single dose of gentamicin in patients with sepsis.Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention.2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the EurLow-dose Gentamicin for Uncomplicated Enterococcus faecalis Bacteremia May be Nephrotoxic in Children.My paper 10 years later: infective endocarditis in the intensive care unit.Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections.Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureusContemporary drug treatment of infective endocarditis.
P2860
Q24185887-5834C984-0759-45B4-999A-56C6B129BBDCQ24198788-F05608B2-9040-41F2-B0FA-06107DED6A3AQ27000445-3E91952A-B53F-4E6D-9A8A-0E8D5F9F9DDBQ30371562-8D61A999-2FB2-47F1-9BA9-5DF0E4B0146EQ33753500-4EE48B1B-2758-4F62-BEF5-8F84B49076C0Q34157657-3F69B5D5-E78A-4D6E-A535-7F120116573EQ34441035-743A1D45-759C-4E2D-81AD-DDF9CCA406C1Q34478074-D4BD0C7C-027E-4044-888B-89873FDBB089Q34611253-0D703ACC-2C3F-4B86-B58D-1699932C4739Q34681219-8EDD7D56-98EF-4933-90A4-2DDF040727D1Q34766191-C6E0DA95-F380-4E54-B706-C921AFEEEFE0Q35066619-C209F3DB-490F-4C29-89E0-24156D0BD46CQ35614568-169902AC-D948-4EA4-AFE2-9E51AC435B1DQ35940556-63C49778-1BC4-478C-9C47-BD29402AD9F7Q36039494-D91D6722-DB61-46DA-A329-6D6697D761B4Q36156077-49D2DDF5-26DD-4456-9FF3-3F1859A43508Q36409472-839A1CF2-8CF1-4AD7-A7EB-E2BCC59DB8E6Q37358638-CA607304-4271-4449-A4C9-27AE0C4119E5Q37800939-903AAA9B-A561-49D2-B4F9-0F73413E5961Q37929895-07CF7159-80E0-497B-9A36-EA7846C71272Q37954711-62F41248-8810-4B1B-8A11-3BAF9BA3403DQ37956597-3DA5FF3D-8222-45D4-85D0-3FE04102DA45Q38070006-985366BA-0FA5-4339-BF74-91475A0BE354Q38090988-639ACBC0-155C-4689-BFC4-D471A96E7D52Q38112810-9A3CBB48-EC2B-4755-9559-81D81AE3E64CQ38145269-DC8064F2-0FD1-471F-BFD3-13F93B546DCAQ38179460-A52A76A1-1695-457A-881F-8A7702886896Q38249103-30D0E68B-BB63-4574-86B1-3C0CD818D107Q38687487-CA9BD458-DCCC-419D-BC7E-D99A3BCC17C5Q38819114-88B04121-19E7-4F13-BE43-16F9B06C0599Q39392178-CBEA786D-D2C9-441A-8DE5-0B99D83CA7C1Q40067736-B390ABB6-F1F0-44BD-A547-E3C855C2CE82Q40322197-5436293F-C998-4557-BD12-B3205E61B15AQ40697398-E05E6B8C-8B30-4460-94B0-64CAED966C7BQ41026009-56A8C2DD-F529-40AB-8BD4-D812DCD84343Q41155969-EACB577A-5EDF-44FD-AB9F-F335D668FE5BQ41732633-1B824744-324F-412C-A9CB-9642B8191928Q41919457-2E42CD41-15A4-40A0-8171-95EA312D8BA4Q42090736-2553806A-F81A-418D-B5C7-5F231ACF560AQ42264366-CCB49F85-832A-4C95-9E9A-737DB9AC709E
P2860
Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Initial low-dose gentamicin fo ...... d endocarditis is nephrotoxic.
@ast
Initial low-dose gentamicin fo ...... d endocarditis is nephrotoxic.
@en
Initial low-dose gentamicin fo ...... d endocarditis is nephrotoxic.
@nl
type
label
Initial low-dose gentamicin fo ...... d endocarditis is nephrotoxic.
@ast
Initial low-dose gentamicin fo ...... d endocarditis is nephrotoxic.
@en
Initial low-dose gentamicin fo ...... d endocarditis is nephrotoxic.
@nl
prefLabel
Initial low-dose gentamicin fo ...... d endocarditis is nephrotoxic.
@ast
Initial low-dose gentamicin fo ...... d endocarditis is nephrotoxic.
@en
Initial low-dose gentamicin fo ...... d endocarditis is nephrotoxic.
@nl
P2093
P356
P1476
Initial low-dose gentamicin fo ...... d endocarditis is nephrotoxic.
@en
P2093
Adolf W Karchmer
Donald P Levine
Elias Abrutyn
G Ralph Corey
Gloria A Vigliani
Helen W Boucher
Henry F Chambers
Mark E Rupp
Sara E Cosgrove
P304
P356
10.1086/597031
P407
P577
2009-03-01T00:00:00Z